Our 3% formulation uses a phospholipid-based delivery system designed to protect the GHK-Cu complex during transit through the lipid-rich outer skin layers and release it at the dermal-epidermal junction
Multivariable logistic regression analyses were performed to predict favourable outcome at 3 months (defined as mRS 0-3) and mortality, adjusted for confounders at admission (age, prior mRS, NIHSS score, ICH volume, intraventricular haemorrhage, infratentorial location), CBP achievement, and OTA times
If a particular pattern appears in one labs BPC-157 work, but cannot be replicated elsewhere even when the same peptide source and methods are used, that suggests either model-specific effects or noise
*JAMA*, 281(15), 1415-1423
Given the pleiotropic beneficial effects of BPC 157, the complexity of the biological systems involved, and the potential risks associated with BPC 157, especially in terms of its interactions with multiple targets across different organs and tissues, the potential for unanticipated adverse effects should be greater
